Merck & Co. logo

Merck & Co. MRK

$ 98.57 -0.95%

Quarterly report 2024-Q3
added 11-06-2024

report update icon

Country

usaUSA

IPO year

-

Industry

Biotechnology

Stock Exchange

NYSESPB

CEO

Mr. Kenneth Frazier

Employees in the company

71 000

Shares

2.54 B

Market Cap[1]

$ 250 B

EBITDA (LTM)

$ 2.77 B

P/E (LTM)

14.12

P/S (LTM)

3.97

EPS (LTM)

7.15

Merck & Co., Inc. is a global pharmaceutical company that specializes in the development, manufacturing, and distribution of innovative medicines, vaccines, and animal health products. Founded in 1891, Merck has grown to become one of the largest pharmaceutical companies in the world, with operations in over 140 countries.

The company's mission is to improve the health and well-being of people and animals around the world. Merck is committed to discovering new treatments and cures for some of the most challenging diseases, including cancer, Alzheimer's disease, and HIV/AIDS. The company has a strong pipeline of products in development, with a focus on immunotherapy and oncology.

Merck is also a leader in the development and distribution of vaccines. The company has played a key role in the fight against infectious diseases such as measles, mumps, rubella, and HPV. Merck's vaccines have saved countless lives around the world and continue to be an important tool in preventing disease outbreaks.

In addition to its pharmaceutical and vaccine business, Merck also has a thriving animal health division. The company develops and manufactures products for livestock, pets, and wildlife. Merck's animal health products are used to prevent and treat diseases in animals, improving their health and welfare.

Merck is committed to operating responsibly and sustainably. The company has set ambitious goals to reduce its environmental impact, improve the health and safety of its employees, and support the communities where it operates. Merck has been recognized for its sustainability efforts, including being named to the Dow Jones Sustainability Index for the past 16 years.

Other stocks of industry "Biotechnology"

Issuer Price % 24h Market Cap Exchange Country
MorphoSys AG MorphoSys AG
MOR
$ 18.96 2.43 % $ 254 M Nasdaq Global Select Market germanyGermany
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M Nasdaq Global Select Market usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 9.1 1.79 % $ 7.59 B Nasdaq Global Select Market niderlandNiderland
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 10.41 -5.36 % $ 43.9 M Nasdaq Global Market usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M Nasdaq Capital Market usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M Nasdaq Global Select Market britainBritain
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 6.96 9.7 % $ 622 M Nasdaq Global Select Market britainBritain
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M Nasdaq Capital Market usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
$ 3.93 -5.76 % $ 99.8 M Nasdaq Capital Market usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M Nasdaq Capital Market usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M NYSE canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M Nasdaq Global Market usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
$ 9.5 - $ 1.7 B Nasdaq Global Select Market usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M Nasdaq Global Select Market usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M Nasdaq Global Select Market usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M Nasdaq Global Market israelIsrael
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 0.41 -6.8 % $ 11.1 M Nasdaq Global Select Market israelIsrael
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
$ 179.68 - $ 10.9 B Nasdaq Global Market,SPB usaUSA
Albireo Pharma Albireo Pharma
ALBO
$ 44.15 -0.23 % $ 916 M Nasdaq Capital Market usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
$ 0.32 - $ 23.9 M Nasdaq Global Select Market usaUSA

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.